Forced Diuresis After Flexible Ureteroscopy for Medium-Sized Renal Stones

NCT ID: NCT07336485

Last Updated: 2026-01-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 2000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-01
• Study Completion Date: 2025-07-01

Brief Summary

This randomized controlled clinical trial evaluated whether furosemide-assisted forced diuresis during flexible ureteroscopy reduced the residual fragment rate and improved the stone-free rate after flexible ureteroscopy for management of medium sized renal stones measuring up to 30 millimeters. Adult patients undergoing flexible ureteroscopy for renal stones were randomized into two parallel groups: an experimental group that received intravenous furosemide during the procedure and a control group that received standard perioperative and postoperative care without furosemide. Stone-free status and residual fragments were assessed using non-contrast computed tomography performed four weeks after the procedure, and residual fragments were classified by fragment size. Secondary outcomes included operative time, length of hospital stay, postoperative complications, total urine output in the first 24 hours, and the need for additional treatments for significant residual stones.

Conditions

Kidney Stones

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Furosemide-Assisted Forced Diuresis During Flexible Ureteroscopy

During flexible ureteroscopy, participants received intravenous furosemide 40 milligrams total, divided into 20 milligrams administered 5 minutes after induction of anesthesia and 20 milligrams administered 30 minutes after the start of the procedure.

Group Type: EXPERIMENTAL

Furosemide

Intervention Type: DRUG

Intravenous furosemide was administered as a total dose of 40 milligrams during the procedure, divided into 20 milligrams given 5 minutes after induction of anesthesia and 20 milligrams given 30 minutes after the start of the procedure.

Standard Care During Flexible Ureteroscopy Without Furosemide

Participants underwent flexible ureteroscopy and received standard perioperative and postoperative care without receiving intravenous furosemide or any other diuretic medication.

Group Type: ACTIVE_COMPARATOR

Standard Care After Flexible Ureteroscopy Without Furosemide

Intervention Type: OTHER

Participants received standard perioperative and postoperative management after flexible ureteroscopy without administration of furosemide or any other diuretic medication.

Interventions

Furosemide

Intravenous furosemide was administered as a total dose of 40 milligrams during the procedure, divided into 20 milligrams given 5 minutes after induction of anesthesia and 20 milligrams given 30 minutes after the start of the procedure.

Intervention Type: DRUG

Standard Care After Flexible Ureteroscopy Without Furosemide

Participants received standard perioperative and postoperative management after flexible ureteroscopy without administration of furosemide or any other diuretic medication.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Adult patients aged 18 years or older.
• Patients who underwent flexible ureteroscopy for renal stones measuring 30 millimeters or less.

Exclusion Criteria

• Patients with active urinary tract infection.
• Patients with a history of previous open renal surgery or renal trauma.
• Patients with contraindications to anesthesia, such as severe cardiac disease, uncontrolled diabetes mellitus, or severe coagulation disorder.
• Patients with severe renal impairment, defined as an estimated glomerular filtration rate less than 30 milliliters per minute per 1.73 square meters.
• Patients with a single kidney.
• Patients with contraindications to furosemide administration.
• Patients with congenital renal anomalies.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ain Shams University

OTHER

Sponsor Role: lead

Responsible Party

Ahmed Nasser Karamany Mokhat

Resident of Urology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Ain Shams University Hospitals (Urology Department)

Cairo, Cairo Governorate, Egypt

Countries

Egypt

Other Identifiers

FMASU MS 685/2025

Identifier Type: -

Identifier Source: org_study_id